Martinez Junior André Miguel, Ruiz Thalles Fernando Rocha, Vilamaior Patrícia Simone Leite, Tiera Vera Aparecida de Oliveira, Taboga Sebastião Roberto, Tiera Marcio José
Department of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences (IBILCE), São Paulo State University (UNESP), R. Cristóvão Colombo 2265, 15054-000, São José do Rio Preto, São Paulo, Brazil.
Department of Biological Sciences, Institute of Biosciences, Humanities and Exact Sciences (IBILCE), São Paulo State University (UNESP), São José do Rio Preto, São Paulo, Brazil.
Drug Deliv Transl Res. 2025 Feb 5. doi: 10.1007/s13346-025-01800-4.
Psoriasis is a chronic inflammatory skin disease that, like other immune-mediated conditions, may benefit from small interfering RNA (siRNA)-based therapies, which are emerging as a promising alternative by addressing several limitations of current treatments. In this study, topical formulations of chitosan-based vectors were developed to deliver siRNA targeting tumor necrosis factor alpha (TNFα) to inflamed skin. Grafting diisopropylethylamine (DIPEA) and polyethylene glycol (PEG) onto the chitosan backbone enhanced siRNA delivery efficiency under physiological conditions, forming robust polymeric vectors with high structural and colloidal stability. These vectors provided siRNA protection against RNAse degradation and oxidative damage. Additionally, the chitosan derivatives displayed lysozyme-mediated biodegradability comparable to native chitosan, while PEG was released in response to reductive environments, supporting controlled vector disassembly. The PEGylated DIPEA-chitosan/siRNA polyplexes demonstrated positive zeta potentials (up to + 11 mV), particle sizes of 100-200 nm, and very low cytotoxicity in keratinocyte and fibroblast cell lines. In vitro, the polyplexes achieved TNFα knockdown levels (65%) in RAW macrophages, comparable to those obtained with Lipofectamine™. Topical formulations showed enhanced interaction of vectors with skin models (Strat-M and porcine ear skin) compared to naked siRNA. Furthermore, in vivo studies indicated that hair follicles were a key route for polyplexes to penetrate deeper skin layers. A rodent model of psoriasis induced by imiquimod was treated topically with these vectors, resulting in approximately a 50% reduction in TNFα levels at inflammation sites, decreased immune cell infiltration, and preservation of epidermal structure. These findings collectively underscore the potential of DIPEA-chitosan-based vectors for topical siRNA-based therapies.
银屑病是一种慢性炎症性皮肤病,与其他免疫介导的疾病一样,可能受益于基于小干扰RNA(siRNA)的疗法,这类疗法正作为一种有前景的替代方案出现,因为它解决了当前治疗方法的几个局限性。在本研究中,开发了基于壳聚糖的载体的局部制剂,以将靶向肿瘤坏死因子α(TNFα)的siRNA递送至炎症皮肤。将二异丙基乙胺(DIPEA)和聚乙二醇(PEG)接枝到壳聚糖主链上可提高生理条件下siRNA的递送效率,形成具有高结构和胶体稳定性的强大聚合物载体。这些载体为siRNA提供了针对RNA酶降解和氧化损伤的保护。此外,壳聚糖衍生物表现出与天然壳聚糖相当的溶菌酶介导的生物降解性,而PEG在还原环境下释放,支持载体的可控分解。聚乙二醇化的DIPEA-壳聚糖/siRNA复合物表现出正的zeta电位(高达+11 mV),粒径为100-200 nm,在角质形成细胞和成纤维细胞系中细胞毒性非常低。在体外,该复合物在RAW巨噬细胞中实现了TNFα敲低水平(65%),与使用Lipofectamine™获得的水平相当。与裸siRNA相比,局部制剂显示载体与皮肤模型(Strat-M和猪耳皮肤)的相互作用增强。此外,体内研究表明毛囊是复合物穿透更深皮肤层的关键途径。用这些载体对咪喹莫特诱导的银屑病啮齿动物模型进行局部治疗,导致炎症部位的TNFα水平降低约50%,免疫细胞浸润减少,表皮结构得以保留。这些发现共同强调了基于DIPEA-壳聚糖的载体用于局部siRNA疗法的潜力。